Figure 2.

Sex differences with tigecycline treatment in the formalin test were seen without ethanol consumption. In female mice (A), tigecycline (80 mg/kg i.p.) increased composite pain scores relative to the control group whereas, in male mice (B), tigecycline decreased composite pain scores in a time‐dependent manner. Analysis of AUC for pain behavior revealed that tigecycline produced pro‐nociception in female (C, D) and antinociception in males (E, F) relative to vehicle in both Phase 1 and Phase 2 of the formalin test. Data are expressed as mean ± SEM (n = 5 to 11 per group); *p = 0.03 for tigecycline versus control group. ANOVA with Bonferroni post hoc testing was completed.